PL4037685T3 - Chinolina modulująca serca i jej zastosowanie w leczeniu chorób - Google Patents

Chinolina modulująca serca i jej zastosowanie w leczeniu chorób

Info

Publication number
PL4037685T3
PL4037685T3 PL21845832.1T PL21845832T PL4037685T3 PL 4037685 T3 PL4037685 T3 PL 4037685T3 PL 21845832 T PL21845832 T PL 21845832T PL 4037685 T3 PL4037685 T3 PL 4037685T3
Authority
PL
Poland
Prior art keywords
serca
quinoline
modulate
treating disease
disease
Prior art date
Application number
PL21845832.1T
Other languages
English (en)
Inventor
Russell Dahl
Original Assignee
Neurodon Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/932,832 external-priority patent/US20200347038A1/en
Application filed by Neurodon Corporation filed Critical Neurodon Corporation
Publication of PL4037685T3 publication Critical patent/PL4037685T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • C07D215/40Nitrogen atoms attached in position 8
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL21845832.1T 2020-07-20 2021-07-19 Chinolina modulująca serca i jej zastosowanie w leczeniu chorób PL4037685T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/932,832 US20200347038A1 (en) 2014-08-29 2020-07-20 Quinolines that modulate serca and their use for treating disease
PCT/US2021/042235 WO2022020261A1 (en) 2020-07-20 2021-07-19 Quinolines that modulate serca and their use for treating disease

Publications (1)

Publication Number Publication Date
PL4037685T3 true PL4037685T3 (pl) 2024-04-02

Family

ID=79729478

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21845832.1T PL4037685T3 (pl) 2020-07-20 2021-07-19 Chinolina modulująca serca i jej zastosowanie w leczeniu chorób

Country Status (11)

Country Link
EP (1) EP4037685B9 (pl)
JP (1) JP7705445B2 (pl)
CN (1) CN116744928A (pl)
CA (1) CA3186668A1 (pl)
DK (1) DK4037685T3 (pl)
ES (1) ES2968041T3 (pl)
FI (1) FI4037685T3 (pl)
HU (1) HUE064550T2 (pl)
PL (1) PL4037685T3 (pl)
PT (1) PT4037685T (pl)
WO (1) WO2022020261A1 (pl)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009014235A (es) * 2007-08-22 2010-04-27 Abbott Gmbh & Co Kg 4-bencilaminoquinolonas, composiciones farmaceuticas que las contiene y su uso.
US20200347038A1 (en) * 2014-08-29 2020-11-05 Russell Dahl Quinolines that modulate serca and their use for treating disease
US10772881B2 (en) * 2017-02-27 2020-09-15 Russell Dahl Quinolines that modulate SERCA and their use for treating disease
US20170281611A1 (en) * 2014-08-29 2017-10-05 Eiger Biopharmaceuticals, Inc. Quinolines and their use for treating endoplasmic reticulum stress-caused diseases
CN106966973A (zh) * 2017-05-18 2017-07-21 湖北工业大学 N‑苯基‑n‑(2‑甲基‑8‑喹啉基)苯甲酰胺的制备方法

Also Published As

Publication number Publication date
WO2022020261A9 (en) 2022-09-09
ES2968041T3 (es) 2024-05-06
JP7705445B2 (ja) 2025-07-09
PT4037685T (pt) 2023-12-28
EP4037685A4 (en) 2022-11-30
HUE064550T2 (hu) 2024-03-28
FI4037685T3 (fi) 2023-11-27
CN116744928A (zh) 2023-09-12
EP4037685A1 (en) 2022-08-10
DK4037685T3 (en) 2024-01-02
JP2023534992A (ja) 2023-08-15
EP4037685B1 (en) 2023-09-20
WO2022020261A1 (en) 2022-01-27
CA3186668A1 (en) 2022-01-27
EP4037685B9 (en) 2024-03-06

Similar Documents

Publication Publication Date Title
EP3968916A4 (en) GLAND TREATMENT DEVICES AND METHODS FOR TREATMENT OF DRY EYES
IL285649A (en) Azepino-indoles and other heterocyclics for the treatment of brain disorders
IL268327A (en) A pharmaceutical preparation for use in the treatment and prevention of c5-related diseases and methods for the treatment and prevention of c5-related diseases
ZA201905222B (en) Combination treating prostate cancer, pharmaceutical composition and treatment method
IL276247A (en) Methods and materials for the treatment of sleep apnea
IL280413A (en) Bismuth-thiol preparations and wound treatment methods
HUE073261T2 (hu) Készítmények fehérje-aggregációs betegségek kezelésére és/vagy megelõzésére
IL285197A (en) Methods and preparations for the treatment of sleep apnea
IL304273A (en) Compositions and methods for treating Fabry disease
IL275875A (en) Treatment and prevention of sleep disorders
EP4334718A4 (en) ASSESSMENT AND TREATMENT OF CANCER
DK4037685T3 (en) Quinoline that modulate serca and its use for treating disease
IL288178A (en) Combined gmci and ddri treatment for cancer
SI3630112T1 (sl) Kombinacija regorafeniba in nivolumaba za zdravljenje raka
ZA202002526B (en) New alcoxyamino derivatives for treating pain and pain related conditions
IL290403A (en) Prevention and treatment of hypoglycemia
IL291609A (en) Methods for treating acute wounds and improving outcomes
EP4085908A4 (en) PHARMACEUTICAL COMBINATION FOR TREATING TUMORS AND ITS APPLICATION
HK40113459A (en) Medicament for preventing and/or treating dry eye
HK40039991A (en) Sleep disorder treatment and prevention
HK40104254A (en) Methods and agents that stimulate mitochondrial turnover for treating disease
SG11202108026UA (en) Neurotensinergic agonists and methods of using same preventing or treating pain
IL288524A (en) Methods of treatment or prevention of eczema
HK40066255A (en) Preventing and treating hypoglycemia
HK40071066A (en) Gmci and ddri combination therapy for treating cancer